Focalin

eLocity's velocity stocks to watch for today are: HEE Corporation (OTC: HCCF), Human Genome Sciences, Inc. (NASDAQ: HGSI), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) and Celgene Corporation (NASDAQ: CELG).

Investors will surely want to keep an eye on HEE Corporation (OTC: HCCF). HEE Corporation announced late in market hours on Tuesday that its proprietary diabetic treatment product, HPB-84, will be featured on HEALTH JOURNAL TELEVISION and CNBC beginning on October 29, 2004.

The HEE Corporation was founded for the purpose of testing and marketing a new and extremely promising neutriceutical treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. In the United States alone, 18.2 million people have diabetes. Diabetes is the fifth leading cause of death by disease in the U.S.

HCCF currently trades at around .07 a share.

On the Nasdaq:

Human Genome Sciences, Inc. (NASDAQ: HGSI)

Biopharmaceutical company Human Genome Sciences, Inc. announced on Tuesday an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon, a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.

Also on Tuesday, Human Genome Sciences, Inc. announced financial results for the three-month and nine-month periods ended September 30, 2004, reporting an actual net GAAP loss of $62.2 million, or $0.48 per share, compared to the actual net loss of $47.7 million, or $0.37 per share, for the same period last year. The Company reported quarterly revenues of $0.7 million, compared to $1.2 million for the same period of last year, with the difference attributed to license and milestone payments paid to Human Genome Sciences in 2003.

HGSI closed Tuesday at $9.75, up 26 cents, on volume of 3 million shares.

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX)

Tuesday, Shares of Onyx Pharmaceuticals, Inc. regained some ground its stock lost on Monday, after the company announced it will delay filing for U.S. approval for a kidney cancer drug it is developing with Germany's Bayer AG.

ONXX closed Tuesday's regular trading session up 9 cents at $27.43, on volume of 2.79 million shares.

Celgene Corporation (NASDAQ: CELG)

Shares of Celgene, a company engaged primarily in the discovery, development and marketing of novel therapies for the treatment of cancer and inflammatory diseases, traded on double its daily average volume on Tuesday and finished the trading session higher by 54 cents at $29.53. On Monday, the company announced that its investigational drug Focalin XR (formerly known as Focalin LA) may help adults and children manage Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms, according to three separate studies presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP).

About eLocity Inc: eLocity owns and operates three financial websites for investors.

-PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.

-StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.

-Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.

Sign up for FREE at any of the sites above.

The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company." The company is to receive compensation for newsletter services for HCCF (Public Company). The compensation is forty thousand dollars from a non-affiliated third party Geneva Bancorp. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.

The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.

The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

Contact: eLocity Inc. 941-544-3498 Thomas Clay